Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Summary by Rutland Herald
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Jul 9, 2026-

3 Articles

The Standard-JournalThe Standard-Journal
Reposted by
Joplin GlobeJoplin Globe
Center

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (Ocrelizumab) for the Treatment of Multiple Sclerosis

TEL AVIV, Israel, and ZUG, Switzerland--(BUSINESS WIRE)--Jul 9, 2026-

·Milton, United States
Read Full Article
Rutland HeraldRutland Herald
Center

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Jul 9, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Rutland Herald broke the news on Thursday, July 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Multiple Sclerosis icon

Multiple Sclerosis

Israel icon

Israel

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal